Market Research Logo

Mylan NV (MYL) - Financial and Strategic SWOT Analysis Review

Mylan NV (MYL) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer, besides anti-rretrovirals, anaphylaxis products and others. The company also offers active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV Key Recent Developments

Feb 28,2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance
Feb 26,2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM
Feb 26,2018: Mylan launches Saugella in India
Nov 20,2017: Mylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference
Nov 10,2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Mylan NV - Key Facts
Mylan NV - Key Employees
Mylan NV - Key Employee Biographies
Mylan NV - Major Products and Services
Mylan NV - History
Mylan NV - Company Statement
Mylan NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Mylan NV - Business Description
Business Segment: Europe
Overview
Performance
Key Stats
Business Segment: North America
Overview
Performance
Key Stats
Business Segment: Rest of World
Overview
Performance
Key Stats
R&D Overview
Mylan NV - SWOT Analysis
SWOT Analysis - Overview
Mylan NV - Strengths
Mylan NV - Weaknesses
Mylan NV - Opportunities
Mylan NV - Threats
Mylan NV - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Mylan NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Mylan NV, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance
Feb 26, 2018: Mylan launches Saugella in India
Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM
Nov 20, 2017: Mylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference
Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange
Nov 06, 2017: Phosphagenics Mylan Arbitration Hearing Concluded
Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance
Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint
Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer
Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Mylan NV, Key Facts
Mylan NV, Key Employees
Mylan NV, Key Employee Biographies
Mylan NV, Major Products and Services
Mylan NV, History
Mylan NV, Other Locations
Mylan NV, Subsidiaries
Mylan NV, Key Competitors
Mylan NV, Ratios based on current share price
Mylan NV, Annual Ratios
Mylan NV, Annual Ratios (Cont...1)
Mylan NV, Annual Ratios (Cont...2)
Mylan NV, Interim Ratios
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Mylan NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Mylan NV, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Mylan NV, Performance Chart (2013 - 2017)
Mylan NV, Ratio Charts
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report